Insulin analogs and use thereof
AssigneeHanmi Pharm. Co., Ltd.
InventorsJin Young Kim, Euh Lim Oh, Jong Soo Lee, Hyung Kyu Lim, In Young Choi, Se Chang Kwon
Life of this patent
Estimating the term…
Abstract
An insulin analog with an improved in vitro effect compared with native insulin, a pharmaceutical composition for treating diabetes containing the insulin analog as an active ingredient, and a method for treating diabetes using the insulin analog or the pharmaceutical composition are described. A nucleic acid encoding the insulin analog, an expression vector including the nucleic acid, a transformant introduced with the expression vector, and a method of producing the insulin analog from the transformant are also described.
Claims6
An insulin analog peptide comprising an A-chain of SEQ ID NO:
- 3 indicated in the following General Formula 1 and a B-chain of SEQ ID NO:
- 4 indicated in the following General Formula 2:
- (General Formula 1)
- Xaa1-Ile-Val-Glu-Xaa2-Cys-Cys-Thr-Ser-Ile-Cys-Xaa3-Leu-Xaa4-Gln-Xaa5-Glu-Asn-Xaa6-Cys-Xaa7 (SEQ ID NO:
- 3)
- wherein
- Xaa1 is alanine, glycine, glutamine, histidine, glutamic acid, or asparagine;
- Xaa2 is alanine, glutamic acid, glutamine, histidine, or asparagine;
- Xaa3 is alanine, serine, glutamine, histidine, or asparagine;
- Xaa4 is aspartic acid;
- Xaa5 is alanine, leucine, tyrosine, histidine, or asparagine;
- Xaa6 is alanine, tyrosine, serine, glutamic acid, histidine, or asparagine;
- and
- Xaa7 is asparagine, glycine, histidine, or alanine;
- and
- (General Formula 2)
- Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Xaa8-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Xaa9-Tyr-Xaa10-Xaa11-Lys-Thr (SEQ ID NO:
- 4)
- wherein
- Xaa8 is tyrosine or is absent;
- Xaa9 is phenylalanine or is absent;
- Xaa10 is threonine;
- and
- Xaa11 is proline or glutamic acid.
Dependencies are inferred from the claim text.